Fc Fusion Therapeutics Market 2024 – Market Size & Segments Analysis, Industry Trends, Manufacturers Analysis, Opportunities and Forecast 2030
Page: 215 | Report Code: LS240823 | Research Suite: Report (PDF) & Market Data (Excel)
The Fc Fusion therapeutics market size was valued at USD 16.6 billion in 2022, and a CAGR of 10.1% is expected during the forecast period. The FC (fragment crystallizable) fusion therapeutics market is a specialized segment within the broader biopharmaceutical industry. FC fusion proteins are engineered by combining the fc region of an antibody with another protein or peptide that has therapeutic potential. This fusion enhances the efficacy and half-life of therapeutic proteins, making it a valuable approach for treating a variety of diseases. Rising prevalence of chronic diseases, such as auto-immune disorders, cancer, and inflammatory diseases, drives the demand for biologics, including Fc fusion therapeutics.
Innovation in protein engineering and drug delivery technologies is propelling the development of more effective and safer FC fusion therapeutics. Many biopharmaceutical companies have a robust pipeline of FC fusion proteins, reflecting their potential to address unmet medical needs. Companies often engage in collaboration to enhance R&D efforts, expand their product portfolio, and gain market access, which drives growth in this market.
Growth Drivers
Rising prevalence of chronic diseases such as rheumatoid
arthritis, auto-immune diseases, cancer, obesity, and diabetes is creating a
demand for effective therapies. FC fusion proteins are explored as treatments
for these conditions due to their ability to enhance efficacy and half-life of
biological drugs. Technological advancements in biotechnology, particularly in
protein engineering and recombinant DNA technology, have enabled the
development of more effective and diverse Fc fusion proteins. Regulatory
approvals of new Fc fusion therapeutics by agencies like the FDA and EMA
contribute to market growth. Pharmaceutical companies are increasingly
investing in research and development of Fc fusion. Collaboration and
partnerships between biotech firms and large pharmaceutical companies help
accelerate the development and commercialization of these therapies. The aging
global population is more susceptible to chronic diseases, with an increase in
demand for Fc fusion proteins, which are being explored for a broader range of
applications beyond autoimmune diseases, cancer, and rheumatoid arthritis.
Emerging economies are witnessing increased healthcare
expenditure and improved access to advanced therapeutics. It creates
opportunities for market expansion in regions like Asia Pacific and Latin
America. Availability of favorable reimbursement policies for biological drugs
in some regions helps in reducing the financial burden on patients, thereby
driving the adoption of Fc fusion therapeutics.
Segmentation
Target Indications
·
Autoimmune Disease
·
Oncology
·
Opthalmology
·
Hematology
·
Others
Type of Fusion Molecule
·
Antibody-Based
·
Cytokin-Based
·
Growth-Factor Based
·
Receptor Extra-Cellular Domain Based
·
Others
Route of Administration
·
Intravenous
·
Subcutaneous
·
Intravitreal
Regional Outlook
·
Asia Pacific
·
North America
·
Latin America
·
Middle East and Africa
·
Europe
Fc Fusion therapeutics Market by Target
Indication Segmentation
On the basis of target indication, the Fc Fusion therapeutics market by target indication is segmented into autoimmune disease, oncology, ophthalmology, hematology, and others. Oncology is the leading segment and is expected to dominate the market during the forecast period, as cancer remains one of the most prevalent and life-threatening diseases in the world. The growing number of cancer cases globally is driving the growth in the market significantly. There is a significant unmet need for effective cancer therapies. Traditional treatments like chemotherapy and radiotherapy have limitations, leading to demand for targeted therapies, which offer better efficacy and reduced side-effects.
Fc-fusion therapeutics are often used in immunotherapy, a rapidly growing field in oncology. These therapies make the immune system better recognize and attack cancer cells. Several Fc fusion protein therapies have shown promising results in clinical trials for various types of cancers. Their success in improving patient outcomes has further solidified oncology as a leading segment in the market. Increasing investment by pharmaceuticals and biotech companies in the development of oncology therapies, including Fc-fusion proteins, is driving growth in the market. Autoimmune diseases are rare diseases, and many patients do not respond to existing therapies, creating a significant need for more effective treatment.
Fc fusion proteins combine the effector function of the Fc region of antibodies
with the biological activity of other proteins. The Fc region of these fusion
proteins extends the half-life of the therapeutic agents, leading to a longer
duration of action and less frequent dosing, which is advantageous for managing
chronic autoimmune diseases. Growing pipeline of Fc fusion protein targeting
autoimmune diseases. Pharmaceutical companies are heavily investing in research
and development in this area, contributing to the segment’s growth.
Regional Outlook
On the basis of the regions, the FC fusion therapeutics market is segmented into 5 parts: Asia Pacific, North America, Latin America, the Middle East and Africa, and Europe. North America, particularly the United States, has a well-established biotech and pharmaceutical R&D infrastructure. Major pharmaceutical companies and numerous biotech companies are headquarters here, driving innovation in FC therapeutics. The FDA has a well-defined and regulatory framework for the approval of biologics, including Fc fusion proteins.
North America has one of the highest healthcare expenditures in the world, which is indirectly enhancing the growth in the market. Significant prevalence of chronic and autoimmune disease in North America, which are among the key therapeutic areas where Fc fusion proteins are utilized. The biologics market in North America is robust and growing, providing a solid foundation for the expansion of Fc fusion therapeutics. Asia Pacific, China, India, Japan, South Korea, and France in particular have rising healthcare expenditures, and due to the large population, there is a large pool of patients suffering from autoimmune disease, cancer, and other chronic diseases, which is driving growth in the market significantly.
Europe is one of the leading segments due to rising healthcare expenditure and the presence of key players in the region. Europe has a well-established healthcare system with robust infrastructure, allowing for the efficient distribution and administration of advanced therapeutics like Fc fusion protein. European medicine agencies have been proactive in reviewing and approving Fc fusion therapeutics, providing a streamlined regulatory pathway. This has encouraged pharmaceutical companies to prioritize Europe in their market strategies. Europe has a significant patient population suffering from chronic conditions like autoimmune disease, and oncology is a primary target for Fc fusion therapy; it creates a strong demand for the treatment.
Key Players
·
Bristol Myers Squibb
·
Sanofi
·
Acceleron Pharmaceuticals
·
Alphamab Oncology
·
Amgen
·
Regeneron Pharmaceuticals
·
Biogen
·
Merck
·
Astrazeneca
· Others Players